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ABSTRACT
Successful cell transplantation for Parkinson’s disease (PD) depends on both an optimal host brain
environment and ideal donor cells. We report that a secreted peptide, neurexophilin 3 (NXPH3), sup-
ports the survival of mouse induced pluripotent stem cell-derived (iPSC-derived) dopaminergic (DA)
neurons in vitro and in vivo. We compared the gene expression profiles in the mouse striatum from
two different environments: a supportive environment, which we defined as 1 week after acute ad-
ministration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), and a nonsupportive environ-
ment, defined as 8 weeks after chronic administration of MPTP. NXPH3 expression was higher in the
former condition and lower in the latter comparedwith untreated controls.Whenwe injectedmouse
iPSC-derivedneural cells alongwithNXPH3 into themouse striatum, the ratioof tyrosinehydroxylase-
positive DA neurons per graft volume was higher at 8 weeks compared with cell injections that ex-
cludedNXPH3. In addition, quantitative polymerase chain reaction analyses of the postmortemputa-
men revealed that the expression level of NXPH3 was lower in PD patients compared with normal
controls. These findings will contribute to optimizing the host brain environment and patient recruit-
ment in cell therapy for PD. STEM CELLS TRANSLATIONALMEDICINE 2015;4:932–944
SIGNIFICANCE
This study identified neurexophilin 3 (NXPH3), a secreted peptide, through comparison of gene expres-
sion profiles in the mouse striatum from various environments generated by different doses of dopa-
minergic (DA) neuron toxin.Whenmouse induced pluripotent stemcell-derived neural cells alongwith
NXPH3 were injected into the mouse striatum, the ratio of DA neurons per graft volume was higher at
8 weeks compared with cell injections without NXPH3. In addition, quantitative polymerase chain re-
action analyses of the postmortem putamen revealed that the expression level of NXPH3 was lower in
patientswith Parkinson’s disease (PD) comparedwith controlswithoutPD. These findings contribute to
optimization of the host brain environment and patient recruitment in cell therapy.
INTRODUCTION
Human induced pluripotent stem cells (iPSCs) pro-
vide a promising source of midbrain dopaminergic
(DA) neurons for cell replacement therapy against
Parkinson’s disease (PD). Protocols for inducing DA
neurons from iPSCs have been developed already
[1–3], andmidbrain DA progenitors can be enriched
[4]. To achieve successful transplantation, however,
the grafted cells need to survive, extend neurites,
and formsynapseswithhostneurons.Consequently,
the outcomeof the transplantation canbe affected
by both the condition of the host brain environ-
ment and the quality of the donor cells [5, 6].
The central nervous system has endogenous
potential to restore lost neurons and repair
neuronal function by recruiting endogenous neural
stem/progenitor cells, suggesting that such stem
cells are plastic and responsive to alternations in
the brain environment [7–9]. In other words, cues
from the host brain can alter the survival and mat-
uration of grafted progenitor cells; therefore, the
identification of endogenous supportive factors
that promote these cues is a strategy for improving
transplantation success.Glial cell-derivedneurotro-
phic factor (GDNF), for example, supports the sur-
vival of grafted midbrain DA neurons, but clinical
application of human recombinant GDNF to treat
PDhasprovenunsuccessfulbecauseofthedevelop-
mentofbindingantibodiesagainsthumanrecombi-
nantGDNF[10].Alternative factors thatsupport the
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To address this issue, we investigated different degrees of
host brain environment with different doses of DA neuron toxin.
Neuroinflammation plays an important role in the pathogenesis
of PD, in which a-synuclein activates microglia to secrete inflam-
matory cytokines such as tumor necrosis factor a (TNF-a), inter-
leukin 1b (IL-1b), and IL-6 [11–13]. These cytokines act directly on
DA neurons or subsequently activate astrocytes. In addition,
allografts inevitably cause inflammation and immune responses
inwhich astrocytes,microglia, and recruited lymphocytes secrete
cytokines such as IL-1b and TNF-a [14] or IL-1b, IL-4, and IL-6 [15]
at the acute phase. Consequently, inflammation would appear to
be a crucial factor in cell transplantation for PD. In the present
study, we generated different degrees of inflammation in host
brain and compared the survival of grafted mouse iPSC-derived
DA neurons in these different conditions. Our observations
allowed us to characterize supportive and nonsupportive brain
environments for cell grafting. By comparing gene expression
profiles between the two brain environments, we found that
a synapse-related peptide, neurexophilin 3 (NXPH3), supported
the survival of the grafted DA neurons. Furthermore, we demon-
strated that single and local administration of NXPH3 increased
the number of DA neurons in iPSC-derived grafts. These results
suggest that NXPH3 is a candidate factor that supports the sur-
vival of iPSC-derived DA neurons.
MATERIALS AND METHODS
Animals
Male 8-week-old C57BL/6NCrSlc mice were purchased from SLC
Inc. (Hamamatsu, Japan, http://www.jslc.co.jp/english/index2.
htm) and cared for and handled according to the guidelines for
animal experiments of Kyoto University. Experimental protocols
were approved by the committee for animal research at Kyoto
University.
Human Brain Tissue
Human brain tissues (n = 11; 6 healthy controls, 5 PD patients)
were provided by the Brain Bank at the TokyoMetropolitan Insti-
tuteofGerontology (Itabashi, Tokyo, Japan). This researchproject
was approved by ethics committees at Kyoto University and
Tokyo Metropolitan Institute of Gerontology.
MPTP Administration
Micewere divided into five groups: two acute groups, 1week and
8weeks after acute administration (4 times every 2 hours) of free
base 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) HCl
(20 mg/kg, 80 mg/kg in total, intraperitoneally; Sigma-Aldrich,
St. Louis, MO, https://www.sigmaaldrich.com); two chronic
groups, 1 week and 8 weeks after chronic administration (once
a day for 20 consecutive days) of free base MPTP HCl (4 mg/kg
per day, 80 mg/kg in total); and a group 1 week after injection
(4 times every 2 hours) of saline (supplemental online Fig. 1).
TheMPTP administrationwas performed in accordancewith previ-
ous reports [16, 17].
Mouse iPSC Culture and Differentiation
Undifferentiated mouse iPSCs (iPS-MEF-Fb/Ng-440A-3) were
used in all experiments [18]. Briefly, this cell line (440A-3) was
established by plasmid vectors that introduced Oct-3/4, Sox2,
Klf4, and c-Myc from mice in which green fluorescent protein
(GFP) and the puromycin-resistant gene are driven by the Nanog
enhancer and promoter [19]. The 440A-3 linewasmost likely free
from plasmid integration into the host genome [18].
Undifferentiated mouse iPSCs were maintained onmitomycin
C-treated mouse embryonic fibroblast (MEF) feeder in Glasgow
minimum essential medium (Gibco-Invitrogen, Grand Island, NY,
http://www.lifetechnologies.com) supplemented with 1% fetal
bovine serum (FBS; JRH Biosciences, Kansas, http://www.
bioscreening.com/Details/JRH-Biosciences.html), 5% knockout
serumreplacement (KSR;Gibco-Invitrogen), 0.1mMnonessential
amino acids (Gibco-Invitrogen), 1 mM pyruvate (Sigma-Aldrich),
0.1mM2-mercaptoethanol (Sigma-Aldrich), 2,000U/ml leukemia
inhibitory factor (Chemicon International, Temecula, CA, http://
www.emdmillipore.com), and 100 U/ml penicillin and 100 mg/
ml streptomycin. The cells were maintained in medium contain-
ing 0.75 mg/ml puromycin to eliminate differentiated cells.
For the neural induction of iPSCs, we used the serum-free cul-
ture of embryoid body-like aggregates with quick reaggregation
(SFEBq) method [20] (supplemental online data).
Cell Transplantation Into Mouse Brain
Onday 12, the iPSC-derived aggregateswere dissociated into single
cells using Accutase (Innovated Cell Technologies, Inc., CA, http://
www.innovativecelltech.com) at 37°C for 5 minutes, and a cell
suspension of approximately 1.5 3 105 cells/ml was prepared in
phosphate-baffered saline ((PBS(2)) containing 30 mM Y-27632
(Wako Pure Chemical Industries, Osaka, Japan, http://www.
wako-chem.co.jp/english). Each mouse received a stereotactic
injection of 1 mL (1 ml/10 seconds) of the cell suspension into the
bilateral striatum (coordinates from the bregma: A +0.5, L and
R +2.0, V +3.0, and incisor bar 0) and was observed for 8 weeks
without immunosuppression.
To examine the effects of soluble factors, GDNF (1 mg/1 ml;
R&D Systems, Minneapolis, MN, http://www.rndsystems.com),
neurexophilin 3 (NXPH3; 1mg/1 ml; R&D Systems), or insulin-
like growth factor (IGF2; 1mg/1 ml; Wako Pure Chemical Indus-
tries) was injected adjacent to the graft (coordinates from the
bregma: A +1.0, L and R +1.5, V +3.0, and incisor bar 0). PBS(2)
was used as a vehicle control.
Reverse Transcription Polymerase Chain Reaction
Total RNA was extracted using an RNeasy Plus Mini kit (Qiagen,
Valencia, CA, http://www.qiagen.com). Then, 1 mg of total RNA
was used for reverse transcription by a SuperScript III First-Strand
Synthesis Systemwith Oligo(dT)20 primer (Invitrogen). For polymer-
ase chain reaction (PCR) amplification, reactions were performed
with Hot Start Taq (Qiagen). The primer sequences and product
sizes are shown in supplemental online Table 1.
Quantitative PCR
Quantitative PCR (qPCR) was performed on a StepOne detec-
tion system (Applied Biosystems, Foster City, CA, http://www.
appliedbiosystems.com). Data analysis was based on the ΔCT
method with normalization of the raw data to Gapdh genes. All
PCRs were performed in triplicate. The primer sequences and
product sizes are shown in supplemental online Table 2.
Immunocytochemistry
For in vitro multiple immunofluorescence, cells were fixed with
4% paraformaldehyde (PFA) in 100 mM phosphate-buffered
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saline (PBS) for 30 minutes. Slides were preincubated with PBS
containing0.1%TritonX-100and2%skimmedmilk for 60minutes
and then incubated at 4°C overnight with primary antibodies
(supplemental online Table 3). Sampleswere then incubatedwith
fluorescent dye-conjugated secondary antibody (diluted 1:500;
Alexa Fluor 488, Alexa Fluor 594, or Alexa Fluor 647; Gibco-
Invitrogen) for 2hours at roomtemperature. In addition, the sam-
ples were incubated with 200 ng/ml of 49,6-diamidino-2-
phenylindole (DAPI; Invitrogen) for nuclei staining. Fluorescence
was then detected using a laser scanning confocal microscope
(FV-1000; Olympus, Tokyo, Japan, http://www.olympus-global.
com/en). Additional processing of images for contrast, color bal-
ance, brightness, and merging was performed as needed with
Fluoview software (version 4.01;Olympus) andAdobePhotoshop
CS (Adobe Systems, San Jose, CA, http://www.adobe.com).
Immunohistochemistry
Micewere perfused through the aortawith 50ml of 100mMPBS,
followed by 20 ml of 4% PFA in PBS, under deep anesthesia with
sodium pentobarbital (100 mg/kg, i.p.). After perfusion, brains
were quickly removed, postfixed for 2 days with 4% PFA in PBS,
and then transferred to 30% sucrose solution in PBS at 4°C. Brain
pieces were sectioned at 30-mm thickness using a cryostat micro-
tome. DAB staining and immunofluorescence were carried out as
described in the supplementary online data.
Evaluation of Histological Analysis
To determine the percentage of positive cells for each marker,
immunopositive cellsweremanually counted for at least three in-
dependent samples. The graft volume was determined by identi-
fying venus-positive (venus+) areas in every sixth 30-mm-thick
section using BZ-II Analyzer software (Keyence, Osaka, Japan,
http://www.keyence.com) and totaling the volumes of whole-
tall cylinders according to Cavalieri’s principle. To estimate the
numberof immunoreactive cells in each graft, the cellswereman-
ually counted in every sixth section. Microglial activation in the
striatum and substantia nigra pars compacta (SNpc) was evalu-
ated by microglial scores [21].
DNA Microarray
Total RNAwas extracted using anRNeasy PlusMini kit, and 100ng
of total RNAwasused for theanalysis. Sampleswerehybridized to
GeneChipMouse Gene 1.0 ST arrays (Affymetrix, Santa Clara, CA,
http://www.affymetrix.com), according to the manufacturer’s
protocol. Arrays were scanned using theMicroarray Scanner Sys-
tem (Agilent Technologies, Santa Clara, CA, http://www.home.
agilent.com). The data were analyzed using GeneSpring GX12.1
software (Agilent Technologies). The expression signals of the
probe sets were calculated using RMA16. The microarray data
are available from the Gene Expression Omnibus (GEO database,
http://www.ncbi.nlm.nih.gov/geo/) with the accession number
GSE60080.
Vector Construction
A pEF1-TetOn-i-Puro/mCherry-i-MCS-3xFLAG vector was con-
structed from pCMV-Tet3G (Clontech Laboratories, Inc., Moun-
tain View, CA, http://www.clontech.com), pTRE3G-mCherry
(Clontech Laboratories, Inc.), linear puromycin marker (Clontech
Laboratories, Inc.), and pCS-EF1-venus (a gift from Dr. Hiroyuki
Miyoshi, BioResourse Center, RIKEN, Tsukuba, Japan). The
3xFLAG sequence was annealed by GCGGCCGCCTAGCAATCGATAA-
CCGATATCGACTATAAAGACCACGATGGAGACTAC and GTAGTC-
TCCATCGTGGTCTTTATAGTCGATATCGGTTATCGATTGCTAGGCG-
GCCGC. The open reading frame of the genes of interest (GOIs)
was amplified from cDNAs derived from human putamen total
RNA, human brain total RNA, or intact mouse striatum total
RNA using PrimeStar (Takara Bio. Inc., Kusatsu, Japan, http://
www.takara-bio.com). The pEF1-TetOn-i-Puro/mCherry-i-MCS-
3xFLAG vector was digested by NotI and EcoRV, and then each
GOI was inserted using InFusion HD (Clontech Laboratories, Inc.).
Establishment of HEK293T Cell Line for In
Vitro Screening
Plasmids were transfected into HEK293T cells by FuGENE6 trans-
fection reagent (Roche, Basel, Switzerland, http://www.roche.
com), and the cells were maintained in Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 10% FBS and
2 mM of L-glutamine. After 24 hours, 10 mg/ml of puromycin
was added into the culture medium to select drug-resistant cells.
The protein expression was induced by 1 mg/ml of doxycycline
(DOX), monitored by mCherry fluorescence and confirmed by
Western blot analysis using a mouse anti-DDDDK antibody
(MBL, Nagoya, Japan, http://www.mbl.co.jp/e). Secretion of
the protein was detected by enzyme-linked immunosorbent as-
say (ELISA) with anti-FLAG high sensitivity, a M2 coated 96-well
plate (Sigma-Aldrich) and a rabbit anti-DDDDK-tag pAb-HRP-
DirecT (MBL).
In Vitro Screening for Candidate Factors
HEK293T cells with the transgene were replated to a six-well
plate. On the next day, iPSC-derived aggregates (day 12) were
plated on these cells and maintained in DMEM/Ham’s F-12 me-
dium with N2 and B27 supplements for 7 days. Secretion of the
transfected gene product was induced by adding 1 mg/ml of
DOX from the first day.
In another evaluation, the iPSC-derived aggregates were dis-
sociated by Accutase and cultured on a dish coated with poly-
L-ornithine/fibronection/laminin (OFL) for 7 days with or without
GDNF (1, 10, 100ng/ml;R&DSystems),NXPH3 (1, 10, 100, 500ng/ml;
R&D Systems), procollagen C-endopeptidase enhancer protein
(PCOLCE; 1, 10, 100, 500 ng/ml; R&D Systems), CXCL9 (1, 10,
100, 500 ng/ml; R&D Systems), or IGF2 (1, 10, 100, 500 ng/ml;
Wako Pure Chemical Industries).
Lentivirus Production and Infection
HEK293T cells were transfected using FuGENE6 transfection
reagent with the plasmid combination pCSII-EF-venus, pCMV-
VSV-G-Rev, andpCAG-HIVgp. The functional infectiousunit of len-
tiviral supernatant was calculated on HEK293T cells. Differentiat-
ing iPSCs were infected with 10 times the number of infectious
particles per cell on day 9 of the differentiation process.
Western Blotting
Striatum and ventralmidbrain sampleswere dissected frommouse
brain. The tissueswere homogenated in CellLyticMTbuffer (Sigma-
Aldrich) supplemented with PhosSTOP (Roche) and CompleteMini
(Roche) as phosphatase inhibitors and protease inhibitors, respec-
tively. Protein concentration was determined using the Bradford
protein assay kit. Sodium dodecylsulfate-polyacrylamide gel
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electrophoresiswas carriedout, as described in the supplementary
online data.
High-Performance Liquid Chromatography Analysis for
Dopamine Release
IPSC-derived aggregates (day 12) were washed twice with low-
concentration KCl solution (4.7 mM KCl) and incubated in low-
concentration KCl solution for 2 minutes. The medium was sub-
sequently replaced with 1 ml of high-concentration KCl solution
(60 mM KCl), and the samples were incubated for 15 minutes.
High-performance liquid chromatography (HPLC) analysis was
performed, as reported previously [4].
Statistical Analysis
Results are given as mean6 SEM. The significance of differences
was determined by Student’s t test for single comparisons and
byone-way analysis of variance formultiple comparisons. Further
statistical analysis for post hoc comparisonswas performed using
Dunnett’s test or Tukey’s test (Prism 5; GraphPad, San Diego, CA,
http://www.graphpad.com).
RESULTS
Induction of DA Neurons From Mouse iPSCs
We inducedmidbrain DAneurons frommouse iPSCs based on the
SFEBq method [20] with the addition of FGF8b and Shh (Fig. 1A).
Dissociated iPSCs quickly reaggregated in each well of 96-well
plates and expanded day by day (Fig. 1B). Nanog-GFP became
invisible before day 7 of the culture (Fig. 1B). Reverse transcrip-
tion PCR analysis showed that the expression of pluripotent cell
markers (Oct-3/4, Nanog) gradually decreased until day 7,
whereas that of neural and neuronal markers (Nestin, Tubb3) in-
creased after day 3 (Fig. 1C). Themarkers ofmidbrain DA neurons
(Lmx1a, Nurr1, Foxa2, and Th) also increased from day 7 to 9
(Fig. 1C). In contrast, markers for the mesoderm (Brachyury)
and endoderm (Sox17) were never observed throughout the
culture (Fig. 1C). Immunofluorescence performed on day 15
revealed that 28.6% 6 4.7% and 65.8% 6 6.2% of the cells
expressed Nestin and Tuj-1, respectively (Fig. 1D, 1E). Among
the Tuj-1+ neurons, 17.1% 6 4.2% of them expressed TH+
(Fig. 1F), and 48.3%6 8.2% of these TH+ neurons also expressed
Nurr1, a midbrain DA neuron marker (Fig. 1G). HPLC analysis
revealed that dopaminewas abundantly released into the culture
mediumof the differentiated cells in response to high potassium-
induced depolarization (14.3 6 0.4 pmol/106 cells) (Fig. 1H).
These in vitro results suggested that our protocol generated func-
tional DA neurons from mouse iPSCs.
Generation of ParkinsonianModels Exhibiting Different
Brain Environments
To identify supportive and nonsupportive host brain environ-
ments for the grafted donor cells, we generated several kinds
of mouse parkinsonian models usingMPTP, fromwhich the mag-
nitude of the pathological conditions can bemodified by the dose
and dosing schedule [22–24]. We generated four types of
MPTP-induced parkinsonianmodels by changing the injection pro-
tocols (high dose over 8 hours vs. low dose over 20 days; total of
80 mg/kg of MPTP for both) and periods (1 week vs. 8 weeks) after
the last injection ofMPTP. Details of the experimental regimens are
described inMaterials andMethods. Briefly, the regimenswere cat-
egorized as (a) 1 week after acute administration (acute-1W), (b)
8 weeks after acute administration (acute-8W), (c) 1 week after
chronic administration (chronic-1W), and (d) 8 weeks after chronic
administration (chronic-8W) (supplemental online Fig. 1).
To investigate differences in host brain environments, we
performed immunofluorescence of the striatum in MPTP-
treated and untreated (control) mice. The degeneration of
DA neuron fibers was apparent in the acute MPTP injection
groups (Fig. 2A, 2E). The activation of Iba+ microglia (Fig. 2B,
2F) and the emergence of GFAP+ reactive astrocytes (Fig. 2C,
2G) were also seen in acute-1W mice. In addition, the number
of CD45+ leukocytes in the striatum increased in acute-1Wmice
compared with control mice (Fig. 2D, 2H). These results sug-
gested that MPTP-induced inflammation occurred in the stria-
tum of acute-1W mice.
Next, we examined the histology of the SNpc among MPTP-
treated and untreatedmice. The number of TH+ neurons was sig-
nificantly reduced in all MPTP-treated groups (supplemental
online Fig. 2A, 2E), as was immunoreactivity to aromatic amino
acid and dopamine transporter (supplemental online Fig. 2A).
The activation of microglia and accumulation of reactive astro-
cytes were also induced in acute-1W mice (supplemental online
Fig. 2B, 2C, 2F, 2G). In contrast, the ratio of a-synuclein+ cells
per TH+ neuron significantly increased in acute-8W, chronic-
1W, and chronic-8W mice (supplemental online Fig. 2D, 2H).
These results suggested that inflammation also occurred in
the SNpc of acute-1W mice and that degenerative changes,
such as a-synuclein accumulation, after MPTP treatment may
occur gradually.
Influence of Different Brain Environments on Grafted
iPSC-Derived Neural Cells
In order to investigate the effects of different conditions in the
host brain, iPSC-derived neural cells were grafted into the stria-
tum of MPTP-treated mice. These cells on day 12 of differentia-
tion were composed of neural cells including those committed
into DA lineage (Fig. 1C). The grafted cells were prelabeled to
express venus (yellow fluorescent protein) by lentiviral transduc-
tion, and their survival was compared 8 weeks after transplanta-
tion. Therewere no statistically significant differences in the graft
volumes among these animals (Fig. 3A, 3B). Similarly, the number
of TH+ neurons in the grafts did not show significant differences
(Fig. 3A, 3C). The ratio of TH+ neurons per graft volume signifi-
cantly increased in acute-1W and acute-8Wmice compared with
control (Fig. 3D). Furthermore, there was a significant difference
between acute-1W and chronic-8Wmice. In the clinical situation
of cell replacement therapy, both thecell numberof surviving TH+
neurons and the graft volume are important parameters for eval-
uating efficacy and safety: an optimal graft provides a larger num-
ber of TH+ neurons in less volume. Consequently, we considered
the ratio of TH+ neurons per graft volume as an index of good
grafting, which led us to define supportive and nonsupportive
brain environments as the acute-1W or chronic-8W brain condi-
tion, respectively.
There aremainly two subtypes ofDAneurons in themidbrain:
A9 in the SNpc and A10 in the ventral tegmental area. These two
subtypes can be distinguished by the expression of G-protein-
gated inwardly rectifying K+ channel subunit (GIRK2) and calbin-
din, respectively [25]. In all grafts, we found both subtypes (Fig.
Nishimura, Murayama, Takahashi et al. 935
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3E, 3G), but there was no difference in the ratio of GIRK2+ or cal-
bindin+ cells per TH+ neuron among the acute-1W and chronic-
8W conditions (Fig. 3F, 3H).
In order to consider the reason for the difference in the ratio
of TH+ neurons between acute-1W and chronic-8W conditions
8 weeks after transplantation, we evaluated early DA differen-
tiation of the grafted cells, name, at 1 week after transplanta-
tion (supplemental online Fig. 3). The ratio of TH+ neurons
(mature DA neurons) in the graft was not significantly different
(supplemental online Fig. 3A, 3B). Similarly, the ratio of Ki67+
Foxa2+ cells per Foxa2+ cells (proliferating DA neuron progen-
itors) in the graft was approximately 7% in the three brain
conditions (supplemental online Fig. 3C, 3D). These results sug-
gested that the increased expansion of DA progenitor cells was
unlikely to contribute to the increase of TH+ neurons in the
acute-1W condition.
Cell injection may cause inflammation around the graft,
and we did not use immunosuppressants; therefore, to investi-
gate inflammation around the graft, we performed immunofluo-
rescence at 1 week after transplantation. Iba-1+ microglia and
CD45+ leukocytes were found around the graft, but they were
restricted to the marginal area and were small in number. Further-
more, they seemed to have similar distribution that was indepen-
dent of MPTP treatment (supplemental online Fig. 4). Theses
results suggest that even if inflammation was evoked in response
to cell injection, the effects did not contribute to differences ob-
served with the different MPTP administration regimens.
Screening of Candidate Genes to Support Grafted
DA Neurons
The results above suggested that the host brains of acute-1W
mice contain more supportive factors for grafted DA neurons
than those of chronic-8Wmice. To identify these factors, we com-
pared gene expressions between the two mice (supplemental
online Fig. 5). We divided genes into two groups. The first in-
cluded genes that increased in the acute-1W condition but de-
creased in the chronic-8W condition compared with control
brains (group 1). The second included those that increased in
the acute-1W condition but were unchanged in the chronic-8W
conditions compared with control brains (group 2). Microarray
analysis followed by secretomeP analysis for selecting secreted
Figure 1. DA neuronal differentiation from induced pluripotent stem cells (iPSCs) using serum-free culture of embryoid body-like aggregates
with quick reaggregation. (A):Protocol of DAneuronal induction from iPSCs under the feeder-free condition. Transplantation experimentswere
performed using day 12 cells. Characteristics of differentiated cells were performed using day 15 cells. (B): Phase-contrast (upper) and GFP
fluorescence (lower) images during differentiation. Scale bar = 500 mm. (C): Reverse transcription polymerase chain reaction analysis during
differentiation of the expression of markers for undifferentiated cells (Oct-3/4, Nanog); neural (Nestin), neuronal (Tubb3), midbrain (Lmx1a,
Nurr1, and Foxa2), and DA neurons (Th); and mesoderm (Brachyury), and endoderm (Sox17). (D–G): Immunofluorescence images of the dif-
ferentiated cells on day 15. Nestin-positive (D) and Tuj-1-positive neurons (E). Double-labeled images for Tuj-1 (green) and TH (magenta) (F) and
TH (green) and Nurr1 (magenta) (G). The blue signal is of nuclei stained with DAPI. Scale bar = 50 mm. (H): High-performance liquid chroma-
tography analysis of the DA release into culture medium by high potassium-evoked depolarization on day 15. Abbreviations: AA, ascorbic acid;
BDNF, brain-derived neurotrophic factor; DA, dopaminergic; DAPI, 49,6-diamidino-2-phenylindole; dbcAMP, dibutyryl cyclic AMP; DMEM/F12;
Dulbecco’smodified Eagle’smediumnutrientmixture F12;DOPAC, 3,4-dihydroxyphenilacetic acid; GDNF, glial cell-derived neurotrophic factor;
GFP, green fluorescent protein; GMEM, Glasgow minimum essential medium; KSR, knockout serum replacement; N2, N2-supplement.
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proteins and a BLAST and UniGene search for conserved genes in
humans resulted in the identification of 30 and 270 genes in the
two groups, respectively. Finally, we confirmed the gene expres-
sion by qPCR anddecided on 6 and 20 candidate genes in groups 1
and 2, respectively (Table 1).
To investigate the function of the products of each candidate,
we established expression vectors for each gene and introduced
them into HEK293T cells (Fig. 4A). The expression of the gene
products was confirmed by Western blot analysis using an anti-
body for FLAG, and product secretion was confirmed by ELISA
(data not shown). GDNF was used as a positive control in this
screening assay because it was reported to facilitate the matura-
tion of DA neurons [26]. Next, we cocultured the iPSC-derived
aggregates (day 12) with HEK293T cells that expressed candidate
Figure 2. Histological analysis of the striatum in each MPTP-treated mouse. (A–D): Representative photomicrographs of striatal TH-pos-
itive (TH+) fibers (A), Iba1+ cells (arrowheads indicate the accumulation of Iba1+ cells) (B), GFAP+ cells (C), and CD45+ cells (arrows) (D).
Scale bars = 500 mm (A) and 100 mm (B–D). (E–H): Quantitative analysis of the protein level of TH (E), microglial activation (F), the protein
level of GFAP (G), and the number of CD45+ cells (H). Each value is given as the mean6 SEM (n = 3–5). p, p, .05; pp, p, .01; ppp, p, .001
versus control group. Abbreviations: 1W, 1week after administration; 8W, 8weeks after administration;MPTP, 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine.
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geneproducts for 7days andevaluated the geneexpression levels
of Th, Lmx1a, and Nurr1 in differentiated cells on day 19 by qPCR
(Fig. 4B). As final candidates, we chose those genes that showed
a fold change greater than 2 compared with control cells using
a mock vector. The final results led us to consider NXPH3, CXCL9,
IGF2, and PCOLCE as well as GDNF.
Because these four proteins are commercially available, we
added each at different concentrations to the culture medium of
iPSC-derived aggregates during days 12–19 and evaluated the ex-
pression level of Th, Lmx1a, and Nurr1 by qPCR (supplemental
online Fig. 6). We chose those proteins that showed a fold change
greater than 1.5 compared with control vehicle and finally decided
to use 100 ng/ml of NXPH3, 100 ng/ml of CXCL9, and 100 ng/ml of
IGF2 in the following experiments.
We examined the effect of these three proteins on iPSC-
derived DA neurons by immunofluorescence. Aggregates were
dissociated and replated onto OFL-coated dishes on day 12 and
cultured for another 7 days with each of the three candidates.
The ratio of TH+neuronsper Tuj-1+ (amarker for postmitotic neu-
rons) neurons was significantly increased when the cells were
treated with 100 ng/ml NXPH3 (Fig. 4D, 4E). When we examined
the proportion ofmidbrain DA neurons, we found that treatment
with 100 ng/ml IGF2 increased the ratio of Nurr1+/TH+ neurons
and Foxa2+/TH+ neurons (Fig. 4F–4I). Based on these results, we
chose NXPH3 and IGF2 as candidates that may support the sur-
vival of iPSC-derived DA neurons.
Immunofluorescence of the striatum revealed that NXPH3
was expressed in NeuN+ (another marker for postmitotic neu-
rons) cells, whereas IGF2 was expressed in GFAP+ (a marker for
astrocytes) cells (Fig. 4J, 4L). Semiquantitative analysis using
Western blot revealed that the protein level in the striatum of
NXPH3 was increased in acute-1W mice but decreased in
chronic-8W mice and that IGF2 was increased in acute-1W mice
(Fig. 5K, 5M).
Figure 3. Histological analysis of induced pluripotent stem cell-derived neural cells 8 weeks after transplantation. (A): Immunofluores-
cence images of grafts for venus (green) and TH (magenta). Scale bar = 500 mm. (B–D): Quantitative analysis of the graft volume
(B), the total number of TH-positive (TH+) neurons (C), and the number of TH+ neurons per graft volume (D). Each value is given as the
mean6 SEM (n = 4–6). p, p, .05; ppp, p, .001. (E): Immunofluorescence images of the grafted neural cells for venus (green), GIRK2 (magenta),
and TH (cyan). Scale bar = 50 mm. (F): Quantitative analysis of the ratio of GIRK2+/TH+ neurons in each graft. Each value is given as the
mean 6 SEM (n = 4–6) with no significant difference. (G): Immunofluorescence images of neural cells for venus (green), calbindin (magenta),
and TH (cyan). Scale bar = 50 mm. (H): Quantitative analysis of the ratio of calbindin+/TH+ neurons in each graft. Each value is given as
the mean6 SEM (n = 4–6) with no significant difference. Abbreviations: 1W, 1 week after administration; 8W, 8 weeks after administration.
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Figure 4. Functional screening of candidate genes by in vitro assay. (A): Schematic drawing of the construct of the Tet-on-inducible mCherry
and 3xFLAG-tagged gene-of-interest (GOI) expression vector. (B): Experimental procedure for the functional screening. Day 12 induced
pluripotent stem cell-derived aggregates were cocultured with GOI-secreting HEK293T cells for 7 days (described in Materials and Methods).
(C):Theeffect ofeach factorwasevaluatedbyaqPCR-basedassay. Eachgenenumber corresponds toTable1. Eachvalue is givenas themean6 SEM
(n = 3–7). (D, F, H): Double-labeled immunofluorescence images for Tuj-1 (green) and TH (magenta) (D), TH (green) and Nurr1 (magenta) (F), TH
(green) and Foxa2 (magenta) (H) with or without each soluble factor. Scale bar = 50 mm. (E, G, I): The ratio of TH+ neurons per Tuj-1+ neuron
(E), Nurr1+ neurons per TH+ neuron (G) and Foxa2+ neurons per TH+ neurons (I). Each value is given as the mean6 SEM (n = 3). p, p, .05 versus
control group. (J, L): Double-labeled immunofluorescence images of the striatum of MPTP-treated mice for NXPH3 (green) and NeuN (magenta)
(J) and for IGF2 (green) and GFAP (magenta) (L). Scale bar = 50 mm (K, M): Semiquantitative analysis of the protein level of NXPH3 (K) and IGF2
(M) in the striatum.Each value is givenas themean6 SEM(n=3).p,p, .05 versus control group;††,p, .01versus acute-1Wgroup.Abbreviations:
acute-1W, 1 week after acute administration; AA, ascorbic acid; BDNF, brain-derived neurotrophic factor; chronic-8W, 8 weeks after chronic ad-
ministration; DAPI, 49,6-diamidino-2-phenylindole; DMEM/F12; Dulbecco’s modified Eagle’s medium nutrient mixture F12; GDNF, glial
cell-derived neurotrophic factor; GMEM, Glasgow minimum essential medium; KSR, knockout serum replacement; MPTP, 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine; N2, N2-supplement; qPCR, quantitative polymerase chain reaction.
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NXPH3 Increased the Ratio of DA Neurons in the Graft
In order to investigate the effects of NXPH3 and IGF2 in vivo, we
grafted iPSC-derived neural cells on day 12 into the striatum of
healthy mice, which have a relatively more stable brain condi-
tion than that of several MPTP-treated mice, and simulta-
neously injected the two proteins into adjacent places. In this
in vivo screening assay, we used PBS and GDNF as negative
and positive controls, respectively. Before transplantation,
we confirmed that the receptors a-neurexin (NRXN) for NXPH3
[27], IGF2 receptor (IGF2R) for IGF2 [28], and GDNF family re-
ceptor a (GFR-a) for GDNF [29] were expressed by the donor
cells (Fig. 5A). At 8 weeks after transplantation, we evaluated
the survival of grafted iPSC-derived DA neurons in the striatum.
Although there were no significant differences in graft volume
or number of TH+ neurons in the grafts (Fig. 5B, 5F, 5G), the
number of TH+ neurons per graft volume was increased in mice
with GDNF and NXPH3 (Fig. 5B–5H). Taken together, these
results indicated that NXPH3 promoted the survival of iPSC-
derived DA neurons in the striatum.
Expression of NXPH3 and IGF2 in PD Patients
To examine whether the expression of NXPH3 or IGF2 is related
to the pathology of PD patients, we analyzed the expression
levels of their mRNAs in the postmortem putamen of healthy
controls and PD patients by qPCR. Age and sex were adjusted
between the two groups (mean age: control, 72.8 6 1.1 years
[n = 6]; PD, 75.0 6 2.6 years [n = 5]) (supplemental online
Table 4). The expression level of NXPH3 was significantly lower
in PD patients compared with healthy controls (Fig. 6A). In con-
trast, the expression of IGF2 was unchanged between the two
groups (Fig. 6B).
DISCUSSION
We constructed an experimental approach to identify effective
soluble factors for cell grafting by comparing gene expression
profiles between supportive and nonsupportive host brain
environments (1 week after acute administration of MPTP
and 8 weeks after chronic administration). We revealed that
NXPH3 increased the ratio of iPSC-derived DA neurons for cell
grafting. In addition, NXPH3 treatment increased the ratio of TH
+ neurons per Tuj1+ neuron in in vitro neural differentiation.
NXPH3 also increased the ratio of TH+ neurons per graft volume
8 weeks after the transplantation of iPSC-derived neural cells
into mouse brain. Furthermore, the expression of NXPH3 was
lower in the postmortem putamen of PD patients than in
healthy counterparts. These results suggest that NXPH3 acts
as a supportive factor for the survival of grafted DA neurons
in the striatum and can be used as a marker for alternations
of the putamen in PD patients.
We observed that the ratio of TH+ neurons per graft volume
was increased at 8 weeks when iPSC-derived neural cells were
grafted into the acute-1W condition compared with the
chronic-8Wone (Fig. 3).However,wedidnotobserve a significant
difference in the ratio of either mature DA neurons (TH+) or pro-
liferating DA progenitor cells (Ki67+ Foxa2+) cells between these
conditions at 1 week after transplantation (supplemental online
Fig. 3). In addition, Ki67+ proliferating cells were not observed in
any grafts at 4 weeks after transplantation (data not shown).
These results suggested that the increase of the TH+ cells was
due to the sustained survival of mature DA neurons rather than
an increased expansion of DA progenitor cells.
NXPH3 is a secreted peptide that binds to the second LNS
domain of synaptic NRXN, a neuronal cell surface receptor
[30]. We found that NXPH3 is expressed by striatal neurons,
and its expression level altered in response to the host brain en-
vironment (Fig. 4J). In addition, donor cells expressed NRXN,
a receptor for the NXPH family (Fig. 5A). A previous report
showed that NXPH3 is strongly expressed in cortical and vesti-
bulocerebellar neurons in adult brains and Cajal-Retzius cells
during development [31]. In addition, Nxph3 knockout mice ex-
hibit a loss of motor coordination and an increase in acoustic
startle response, suggesting that NXPH3 is involved in the syn-
aptic transmission of motor and acoustic function [31]. NXPH-
NRXN interaction is able to stabilize the synaptic function by
contributing to synaptic plasticity [32]. In the neuronal develop-
mental process, stimuli via synaptic formation play a key role in
the survival and maturation of newly generated neurons [33].
These reports led us to speculate that upregulation of NXPH3
promoted neuronal plasticity after MPTP-induced brain injury
Figure 4. Continued from previous page.
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and that the resulting synaptic stability supported the survival
of grafted DA neurons. Further work is required to confirm this
hypothesis.
Another candidate supportive factor for graftedDAneurons is
IGF2, which increased the ratio of TH+ neurons that simulta-
neously expressed the midbrain markers Nurr1 and Foxa2 during
neural differentiation in vitro. IGF2 is a secreted peptide that
belongs to the IGF/IGFBP (IGF/IGF binding protein) family, which
plays important roles in somatic mitosis, development, tissue re-
pair, and regeneration [34]. IGF2 was also reported to promote
DA differentiation from human embryonic stem cells [35]; how-
ever, despite our in vitro results and the findings noted, the local
and single administration of IGF2 had no effect on the survival of
iPSC-derived DA neurons in vivo.
Previous studies on postmortem brains reported that the
expression levels of several genes in the SNpc and putamen
differ between healthy controls and PD patients [36, 37].
Furthermore, oxidative/nitrosative stress and mitochondrial
dysfunction based on changes in 3-nitrtyrosine and glutathione
can characterize alternations in the PD brain and thus can act
as possible markers for PD [38]. We found that expression of
the NXPH3 gene in the postmortem putamen was significantly
lower in PD patients. We speculate that the long-term decline
of neuronal connections in the putamen of PD patients may
lead to the reduced expression of NXPH3. Because the puta-
men is a target area for cell transplantation in clinical trials
[39–41], an expression profile of the putamenmay offer impor-
tant information for predicting whether or not a target area is
favorable. In a double-blinded randomized clinical study, trans-
plantation of embryonic DA neurons showed some benefits in
PD patients aged 60 years old and younger but not in older
patients [42], suggesting that the host brain environment is im-
portant for the success of cell replacement therapy for PD. Tak-
ing all these findings together, the expression level of NXPH3 in
the putamen may be a suitable marker for appropriate patient
recruitment in PD treatment.
Figure 5. Effect of soluble factors on induced pluripotent stem cell-derived (iPSC-derived) dopaminergic neurons in vivo. (A): Western blot
analysis of receptors for GFR-a, a-NRXN and IGF2R. (B–E): Histological analysis of iPSC-derived grafts at 8 weeks with the indicated factor. Im-
munofluorescence images for venus (green) and TH (magenta). Scale bar = 50mm. (F–H):Quantitative analysis of the graft volume (F), the total
number of TH-positive (TH+) neurons (G), and the number of TH+ neurons per graft volume (H). Each value is given as themean6 SEM (n = 5–6).
p, p, .05 versus PBS(2) control group. Abbreviation: PBS(2), phosphate-buffered saline.
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CONCLUSION
We established an experimental strategy for identifying ef-
fective factors for cell transplantation in PDbased on a compar-
ative study of several brain environments. Accordingly, we
succeeded in identifying NXPH3 as a new supportive factor
for cell transplantation. We also found that the expression
level of NXPH3 in the postmortem putamen of PD patients
was decreased compared with control, suggesting that NXPH3
may be a useful biomarker for PD patients. These findings are
expected to contribute to future human trials using iPSC-
derivedDAneurons and promote both in vivo and in vitro appli-
cations of stem cell technology.
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